10. Prior chemotherapy/radiotherapy/investigational therapy within 2 weeks before the start of study drugs with the following exceptions: a. To reduce the circulating lymphoblast count or palliation: steroids, hydroxyurea. No washout necessary for these agents. b. For ALL maintenance/CML treatment: mercaptopurine, methotrexate, vincristine, single-agent, single-dose fo cytarabine and/or tyrosine kinase inhibitors. These agents should be discontinued at least 48 hours prior to start of study drugs. (Note: the interval of time from last dose of any approved TKI to start of protocol treatment is 48 hours regardless of the indication for treatment with the TKI.)